Pyrazolo Cinnolin-3-one M1 Allosteric Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's Disease, particularly those targeting muscarinic M1 receptors, face challenges such as side effects like sweating, nausea, and diarrhea, and do not effectively address the underlying disease pathology, while existing therapies like acetylcholinesterase inhibitors provide only symptomatic relief.
Innovation Solution
Development of novel pyrazolo[4,3-c]cinnolin-3-one compounds that act as muscarinic M1 receptor positive allosteric modulators, which can be used to treat Alzheimer's Disease and other disorders by enhancing the affinity of muscarinic ligands to the M1 receptor, potentially altering APP processing and preventing Aβ peptide formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional M1 receptor ligands are used to treat Alzheimer's Disease, then cognitive enhancement is achieved, but side effects such as sweating, nausea, and diarrhea occur
Solution Approach 1:
The patent introduces positive allosteric modulators as intermediary substances that bind to allosteric sites on the M1 receptor rather than competing directly with acetylcholine at the orthosteric site. These modulators enhance the receptor's response to acetylcholine in a cooperative manner, providing cognitive enhancement while avoiding the direct competitive inhibition that causes side effects. The modulator acts as a mediator that amplifies the natural neurotransmitter's effect without blocking its normal function.
Solution Approach 2:
The patent modifies the pharmacological parameters of M1 receptor activation by changing the binding mechanism from competitive inhibition to positive allosteric modulation. This parameter change allows for enhanced receptor response with reduced off-target effects, as the modulators bind to distinct allosteric sites and produce cooperative enhancement rather than direct competition with acetylcholine.
2Ease of operation
If acetylcholinesterase inhibitors are used to treat Alzheimer's Disease, then symptomatic relief is provided, but the underlying disease pathology is not addressed
Solution Approach 1:
The patent extracts the therapeutic mechanism from purely symptomatic treatment by targeting the underlying disease mechanism through M1 receptor allosteric modulation. Instead of only inhibiting acetylcholinesterase to increase acetylcholine levels, the invention directly modulates the M1 receptor's response to acetylcholine, thereby addressing the downstream pathological effects including APP processing and Aβ formation while maintaining cognitive enhancement.
Solution Approach 2:
The patent implements preliminary action by preventing Aβ peptide formation and altering APP processing before these pathologies fully develop and cause cognitive decline. The positive allosteric modulators proactively intervene in the disease mechanism by enhancing M1 receptor signaling that prevents Aβ production, rather than merely reacting to symptomatic manifestations.
3Reliability
If M1 receptor agonists are used to treat Alzheimer's Disease, then underlying disease mechanism is targeted, but side effects are produced
Solution Approach 1:
The patent uses positive allosteric modulators as intermediary substances that enhance M1 receptor function without directly activating it in the competitive manner that causes side effects. These modulators bind to allosteric sites and cooperatively enhance the receptor's response to endogenous acetylcholine, providing disease mechanism targeting while avoiding the harmful effects of direct agonist activation.
Solution Approach 2:
The patent substitutes the direct agonist mechanism with an allosteric modulation mechanism. Instead of directly activating the receptor through competitive binding (the mechanical system that causes side effects), the invention uses allosteric modulators that change the receptor's conformational state and enhance its response to acetylcholine, replacing the direct activation mechanism with a modulatory one that avoids side effects.
Data Source
AI summary
The present invention is directed to pyrazolo[4,3-c]cinnolin-3-one compounds of formula (I)which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.